Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Assembly Biosciences, Inc.

Market Cap 479M 413M 380M 357M 671M 45.17B 677M 4.5B 1.75B 22.17B 1.8B 1.76B 76.68B P/E 2026 *
-22.3x
P/E 2027 * -8.42x
Enterprise Value 479M 413M 380M 357M 671M 45.17B 677M 4.5B 1.75B 22.17B 1.8B 1.76B 76.68B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 14.8x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+2.03%
1 week+9.43%
Current month-10.86%
1 month-10.08%
3 months-10.41%
6 months-23.79%
Current year-27.51%
1 week 22.35
Extreme 22.35
25.93
1 month 21.8
Extreme 21.795
31.89
Current year 21.8
Extreme 21.795
34.68
1 year 16.5
Extreme 16.5
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
50.04
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 2022-12-31
Director of Finance/CFO - 2025-06-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 2011-12-31
Chairman 80 2015-02-09
Director/Board Member 61 2017-12-13
Date Insider Type Main position Quantity % Market Cap.
06-03Free

Director

8,000 0.0514%
06-03Free

Director

8,000 0.0514%
06-03Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+2.03%+9.43%+43.84%+92.02% 479M
-0.56%-0.51%-12.53%-10.84% 43.44B
+1.35%+6.90%+299.50%+521.18% 33.54B
-2.81%-8.55%+7.10%-22.96% 28.48B
+2.70%+4.15%+7.24%+41.50% 29.2B
+0.06%+4.36%+13.31%+21.11% 25.34B
+1.61%+8.45% - - 14.36B
-0.18%-3.82%+50.96%+102.83% 13.05B
-0.03%-2.83%+3.34%+4.20% 12.67B
-0.85%+0.15%+99.76%+80.01% 12.28B
Average +0.34%+2.04%+56.95%+92.12% 21.28B
Weighted average by Cap. +0.16%+1.37%+61.49%+103.41%

Financials

2026 *2027 *
Net sales 45.47M 39.23M 36.06M 33.95M 63.79M 4.29B 64.32M 427M 166M 2.11B 171M 167M 7.29B 32.25M 27.82M 25.58M 24.08M 45.24M 3.04B 45.62M 303M 118M 1.49B 121M 118M 5.17B
Net income -20.46M -17.65M -16.23M -15.28M -28.71M -1.93B -28.95M -192M -74.88M -948M -76.8M -75.16M -3.28B -56.38M -48.64M -44.72M -42.09M -79.09M -5.32B -79.75M -530M -206M -2.61B -212M -207M -9.03B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
26-06-18 24.66 $ +2.09% 72,845
26-06-17 24.15 $ +3.51% 133,827
26-06-16 23.33 $ -0.04% 116,938
26-06-15 23.34 $ +1.66% 173,207
26-06-12 22.96 $ +1.91% 144,394
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
24.15USD
Average target price
50.00USD
Spread / Average Target
+107.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!